| Accession |
PRJCA023289 |
| Title |
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma |
| Relevance |
Medical |
| Data types |
cytogenetic FISH testing
|
| Organisms |
Homo sapiens
|
| Description |
This is a Phase 1/2 study; Phase 1 includes Part 1 and Part 2, and the Phase 2 component is Part 3. This study will enroll subjects with relapsed or refractory multiple myeloma. In Part 3, China Cohort, approximately 25 Chinese subjects will be enrolled with multiple myeloma who are triple class exposed (PI, IMiD, and anti-CD38 monoclonal antibody) and have previously received treatment with greater than or equal to 3 prior lines of therapy (same as Cohort A Part 3). |
| Sample scope |
Multiisolate |
| Release date |
2024-01-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Janssen Research & Development, LLC
|
|
2021LP00840/2021LP00841
|
|
|
|
| Submitter |
Ting
Niu (tingniuhx@163.com)
|
| Organization |
West China Hospital of Sichuan University |
| Submission date |
2024-01-29 |
